TY - JOUR
T1 - Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia
AU - Miodownik, Chanoch
AU - Meoded, Aviel
AU - Libov, Igor
AU - Bersudsky, Yuly
AU - Sela, Ben Ami
AU - Lerner, Vladimir
PY - 2008/7
Y1 - 2008/7
N2 - Background: Motor disturbances in vitamin B6-deficient animals were described. Some clinical experiments showed that vitamin B6 may ameliorate different drug-induced movement disorders, including tardive dyskinesia (TD). The aim of this study was to compare plasma pyridoxal-5-phosphate (PLP) levels in schizophrenic patients with and without TD. Method: This study was conducted in the Be'er Sheva Mental Health Center from February 2006 to August 2006. Eighty-nine schizophrenic inpatients (40 have TD, 22 men and 18 women, 20-66 yrs old [mean, 48 yrs] and 49 schizophrenic inpatients, 30 men and 19 women, 21-66 yrs old (mean, 49 yrs), without any symptoms of motor disturbances [the control group]) were enrolled in the study. Measurement of PLP is performed by high-performance liquid chromatography separation in all patients. Results: There was a significant difference in plasma PLP levels between patients with TD and those without TD. The discrepancy between the groups was almost entirely attributable to the PLP levels of male patients: 12.4 ± 11.4 vs 29.0 ± 12.9 nM in men (P < 0.001), and 19.7 ± 14.8 vs 22.0 ± 13.6 nM in women (P > 0.5). Conclusions: Our results suggest that schizophrenic and schizoaffective male patients with TD have lower PLP plasma levels than non-TD patients.
AB - Background: Motor disturbances in vitamin B6-deficient animals were described. Some clinical experiments showed that vitamin B6 may ameliorate different drug-induced movement disorders, including tardive dyskinesia (TD). The aim of this study was to compare plasma pyridoxal-5-phosphate (PLP) levels in schizophrenic patients with and without TD. Method: This study was conducted in the Be'er Sheva Mental Health Center from February 2006 to August 2006. Eighty-nine schizophrenic inpatients (40 have TD, 22 men and 18 women, 20-66 yrs old [mean, 48 yrs] and 49 schizophrenic inpatients, 30 men and 19 women, 21-66 yrs old (mean, 49 yrs), without any symptoms of motor disturbances [the control group]) were enrolled in the study. Measurement of PLP is performed by high-performance liquid chromatography separation in all patients. Results: There was a significant difference in plasma PLP levels between patients with TD and those without TD. The discrepancy between the groups was almost entirely attributable to the PLP levels of male patients: 12.4 ± 11.4 vs 29.0 ± 12.9 nM in men (P < 0.001), and 19.7 ± 14.8 vs 22.0 ± 13.6 nM in women (P > 0.5). Conclusions: Our results suggest that schizophrenic and schizoaffective male patients with TD have lower PLP plasma levels than non-TD patients.
KW - Plasma level
KW - Pyridoxal-5-phosphate
KW - Tardive dyskinesia high-performance liquid chromatography separation
KW - Vitamin B6
UR - http://www.scopus.com/inward/record.url?scp=53449097426&partnerID=8YFLogxK
U2 - 10.1097/WNF.0b013e3181506623
DO - 10.1097/WNF.0b013e3181506623
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18670243
AN - SCOPUS:53449097426
SN - 0362-5664
VL - 31
SP - 197
EP - 203
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
IS - 4
ER -